Cloning and Expression of Recombinant VP2 Capsid Protein Gene of Canine Parvovirus in E. coli System

Sangeetha, S.; Mukhopadhyay, H. K.; Srinivas, Mouttou Vivek; Muthuraj, Muthusivaramapandian; Antony, P. X.; Thanislass, J.

doi:10.20546/ijcmas.2018.710.284

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, many platforms have been established to develop vaccines with high e ciency and safety pro les [19], of which VLPs have attracted the most attention in the veterinary vaccine eld [20][21][22], especially in pet vaccines. Many researchers have tried to express VP2 protein through various expression systems, such as Escherichia coli [23][24][25], insect cell baculovirus [7,11,26,27], or even silkworm [28]. These expression systems each have their own advantages and disadvantages.…”

Section: Discussionmentioning

confidence: 99%

Baculovirus Expression of Feline Panleukopenia Virus Capsid Protein and Induces Robust Immune Responses in Cats

Feng,

Yan,

Shang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Feline panleukopenia (FP) is a highly contagious, often fatal viral disease that suffered by almost all members of the family Felidae. Feline panleukopenia virus (FPLV) is the major etiological pathogen of FP, which is a single-stranded, non-enveloped DNA virus. The VP2 protein is the major protective antigen of FPLV and be considered as a promising candidate for developing a novel subunit vaccine to immunoprophylaxis of FP. Results FPLV-VLPs was created by expressing VP2 protein in a baculovirus expression vector system (BEVS), and it showed higher antigenicity and higher hemagglutination (up to 1:214). Cats vaccinated with the FPLV-VLP vaccine produced a higher level of anti-FPLV HI antibodies (1:216) and were 100% protected from challenge with virulent FPLV. Methods In this study, the gene encoding FPLV VP2 (GenBank OP491797) was codon optimized and obtained by gene splicing by overlap extension PCR(SOE PCR). Then, the optimized VP2 sequence was ligated to the pFastBac-I vector through homologous recombination technology. Finally, VP2 protein was expressed in a baculovirus expression vector system (BEVS) and it self-assemble into virus-like particles after treated with 100 mM NaHCO3 solution. Conclusion In summary, FPLV-VLPs with higer antigenicity and higher hemagglutination (up to 1:214), was created by expressing VP2 protein in a baculovirus expression vector system (BEVS). Then, a novel a novel pet vaccine against FP with a higher effectiveness and safety profile was developed in this study. Cats vaccinated with the FPLV-VLP vaccine produced a higher level of anti-FPLV HI antibodies (1:216) and were 100% protected from challenge with virulent FPLV. In subsequent applications, the FPLV-VLP vaccine can be used as a single vaccine or in combination with other vaccines to vaccinate cats for immunoprophylaxis against FPs.

show abstract